SPECIAL EDITION:
GASTROENTEROLOGY
BRINGING RESEARCH INTO PRACTICE SUMMER 2016
19%
5-10%
of the U.S. population will develop nonalcoholic fatty liver disease
of those undergoing ERCP will develop pancreatitis
3–9%
11%
of reported adverse drug reactions relate to drug-induced liver injury
24%
of women in the U.S. are affected by pelvic floor dysfunction
of people worldwide are affected by IBS
4.5%
of the U.S. population will be diagnosed with colon and rectal cancer
20%
of people in the U.S. are affected by gastrointestinal diseases every year